Does the media prefer FTH or SRPT?

In the previous week, Sarepta Therapeutics had 15 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 7 mentions for Sensei Biotherapeutics. Sarepta Therapeutics' average media sentiment score of 0.38 beat Sensei Biotherapeutics' score of 0.13 indicating that Sarepta Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sarepta Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has better valuation & earnings, COAG or FTH?

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A -$24.78 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$138.82 N/A

Is COAG or FTH more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Sensei Biotherapeutics N/A -392.57% -141.72%

Does the media favor COAG or FTH?

In the previous week, Hemab Therapeutics had 6 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for Hemab Therapeutics and 7 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.13 beat Hemab Therapeutics' score of 0.01 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, FTH or TRAX?

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$138.82 N/A First Tracks Biotherapeutics N/A N/A N/A -$2.79 N/A

Is FTH or TRAX more profitable?

First Tracks Biotherapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -392.57% -141.72% First Tracks Biotherapeutics N/A N/A N/A

Which has preferable valuation and earnings, FTH or MESO?

Sensei Biotherapeutics has higher earnings, but lower revenue than Mesoblast. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sensei Biotherapeutics N/A N/A -$21.08M -$138.82 N/A Mesoblast $120.25M 14.77 -$57.50M N/A N/A

Is FTH or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -392.57% -141.72% Mesoblast N/A N/A N/A

Does the media favor FTH or MESO?

In the previous week, Mesoblast had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for Mesoblast and 7 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.13 beat Mesoblast's score of 0.11 indicating that Sensei Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mesoblast 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Is FTH or VIR more profitable?

Vir Biotechnology's return on equity of -21.38% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -392.57% -141.72% Vir Biotechnology N/A -21.38% -16.97%

Does the media prefer FTH or VIR?

In the previous week, Vir Biotechnology had 51 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 58 mentions for Vir Biotechnology and 7 mentions for Sensei Biotherapeutics. Vir Biotechnology's average media sentiment score of 0.52 beat Sensei Biotherapeutics' score of 0.13 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 13 Very Positive mention(s) 10 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sensei Biotherapeutics (FTH) Competitors

$11.56 -1.79 (-13.44%)

As of 01:06 PM Eastern

Compare

FTH vs. SRPT, COAG, TRAX, MESO, and VIR

Should you buy Sensei Biotherapeutics stock or one of its competitors? Sensei Biotherapeutics's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Hemab Therapeutics (COAG), First Tracks Biotherapeutics (TRAX), Mesoblast (MESO), and Vir Biotechnology (VIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sensei Biotherapeutics compare to Sarepta Therapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and Sarepta Therapeutics (NASDAQ:SRPT) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Sensei Biotherapeutics has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$138.82	N/A
Sarepta Therapeutics	$2.20B	0.81	-$713.41M	-$1.37	N/A

Sensei Biotherapeutics has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -5.86%. Sarepta Therapeutics' return on equity of -0.20% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-392.57%	-141.72%
Sarepta Therapeutics	-5.86%	-0.20%	-0.09%

Sensei Biotherapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Sensei Biotherapeutics currently has a consensus target price of $56.58, indicating a potential upside of 323.85%. Sarepta Therapeutics has a consensus target price of $23.67, indicating a potential upside of 41.89%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Sarepta Therapeutics	6 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Sarepta Therapeutics had 15 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 7 mentions for Sensei Biotherapeutics. Sarepta Therapeutics' average media sentiment score of 0.38 beat Sensei Biotherapeutics' score of 0.13 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sarepta Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Sensei Biotherapeutics and Sarepta Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Hemab Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Sensei Biotherapeutics	N/A	-392.57%	-141.72%

Hemab Therapeutics presently has a consensus target price of $56.00, suggesting a potential upside of 42.38%. Sensei Biotherapeutics has a consensus target price of $56.58, suggesting a potential upside of 323.85%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sensei Biotherapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Hemab Therapeutics had 6 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 13 mentions for Hemab Therapeutics and 7 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.13 beat Hemab Therapeutics' score of 0.01 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Hemab Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$138.82	N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Hemab Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to First Tracks Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:FTH) and First Tracks Biotherapeutics (NASDAQ:TRAX) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

Sensei Biotherapeutics currently has a consensus target price of $56.58, indicating a potential upside of 323.85%. First Tracks Biotherapeutics has a consensus target price of $72.17, indicating a potential upside of 42.82%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sensei Biotherapeutics is more favorable than First Tracks Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
First Tracks Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

First Tracks Biotherapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$138.82	N/A
First Tracks Biotherapeutics	N/A	N/A	N/A	-$2.79	N/A

First Tracks Biotherapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-392.57%	-141.72%
First Tracks Biotherapeutics	N/A	N/A	N/A

In the previous week, Sensei Biotherapeutics had 5 more articles in the media than First Tracks Biotherapeutics. MarketBeat recorded 7 mentions for Sensei Biotherapeutics and 2 mentions for First Tracks Biotherapeutics. First Tracks Biotherapeutics' average media sentiment score of 0.92 beat Sensei Biotherapeutics' score of 0.13 indicating that First Tracks Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
First Tracks Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Sensei Biotherapeutics beats First Tracks Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Mesoblast?

Sensei Biotherapeutics (NASDAQ:FTH) and Mesoblast (NASDAQ:MESO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Mesoblast's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-392.57%	-141.72%
Mesoblast	N/A	N/A	N/A

In the previous week, Mesoblast had 1 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 8 mentions for Mesoblast and 7 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.13 beat Mesoblast's score of 0.11 indicating that Sensei Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sensei Biotherapeutics currently has a consensus price target of $56.58, suggesting a potential upside of 323.85%. Mesoblast has a consensus price target of $39.00, suggesting a potential upside of 185.71%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sensei Biotherapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Sensei Biotherapeutics has higher earnings, but lower revenue than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$138.82	N/A
Mesoblast	$120.25M	14.77	-$57.50M	N/A	N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 7.0% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Sensei Biotherapeutics beats Mesoblast on 7 of the 13 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Vir Biotechnology?

Sensei Biotherapeutics (NASDAQ:FTH) and Vir Biotechnology (NASDAQ:VIR) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation.

Sensei Biotherapeutics has a beta of -0.15, suggesting that its share price is 115% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Sensei Biotherapeutics presently has a consensus price target of $56.58, indicating a potential upside of 323.85%. Vir Biotechnology has a consensus price target of $22.57, indicating a potential upside of 71.91%. Given Sensei Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Vir Biotechnology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Sensei Biotherapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$138.82	N/A
Vir Biotechnology	$68.56M	32.80	-$437.99M	-$1.26	N/A

Vir Biotechnology's return on equity of -21.38% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-392.57%	-141.72%
Vir Biotechnology	N/A	-21.38%	-16.97%

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Vir Biotechnology had 51 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 58 mentions for Vir Biotechnology and 7 mentions for Sensei Biotherapeutics. Vir Biotechnology's average media sentiment score of 0.52 beat Sensei Biotherapeutics' score of 0.13 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	13 Very Positive mention(s)	10 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vir Biotechnology beats Sensei Biotherapeutics on 8 of the 15 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$298.65M	$4.16B	$7.90B	$12.27B
Dividend Yield	N/A	3.63%	2.45%	4.52%
P/E Ratio	-0.08	25.24	35.13	30.94
Price / Sales	N/A	15.17	8.24	5.46
Price / Cash	N/A	26.63	22.08	22.51
Price / Book	1.85	4.14	4.47	3.80
Net Income	-$21.08M	-$22.78M	$3.51B	$390.82M
7 Day Performance	-41.99%	1.73%	1.14%	2.36%
1 Month Performance	-50.30%	-7.09%	-4.38%	-6.22%
1 Year Performance	N/A	-2.68%	-0.15%	-6.57%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	2.9424 of 5 stars	$11.56 -13.4%	$56.58 +389.6%	N/A	$298.65M	N/A	N/A	29	Positive News Analyst Forecast
SRPT Sarepta Therapeutics	3.7118 of 5 stars	$18.54 +1.2%	$22.88 +23.4%	-7.2%	$1.94B	$2.20B	N/A	835	Earnings Report Analyst Upgrade
COAG Hemab Therapeutics	2.701 of 5 stars	$43.10 +4.7%	$54.71 +26.9%	N/A	$1.92B	N/A	N/A	59	News Coverage Earnings Report Analyst Forecast
TRAX First Tracks Biotherapeutics	3.8033 of 5 stars	$46.34 +2.9%	$71.33 +53.9%	N/A	$1.89B	N/A	N/A	104	Positive News Analyst Downgrade Gap Down
MESO Mesoblast	2.0704 of 5 stars	$14.77 +1.6%	$39.00 +164.0%	-12.1%	$1.89B	$120.25M	N/A	108	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. SRPT, COAG, TRAX, MESO, and VIR

How does Sensei Biotherapeutics compare to Sarepta Therapeutics?

Summary

How does Sensei Biotherapeutics compare to Hemab Therapeutics?

Summary

How does Sensei Biotherapeutics compare to First Tracks Biotherapeutics?

Summary

How does Sensei Biotherapeutics compare to Mesoblast?

Summary

How does Sensei Biotherapeutics compare to Vir Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. SRPT, COAG, TRAX, MESO, and VIR

How does Sensei Biotherapeutics compare to Sarepta Therapeutics?

Which has preferable earnings and valuation, FTH or SRPT?

Is FTH or SRPT more profitable?

Which has more volatility & risk, FTH or SRPT?

Do institutionals & insiders have more ownership in FTH or SRPT?

Do analysts recommend FTH or SRPT?

Does the media prefer FTH or SRPT?

Summary

How does Sensei Biotherapeutics compare to Hemab Therapeutics?

Is COAG or FTH more profitable?

Do analysts recommend COAG or FTH?

Does the media favor COAG or FTH?

Which has better valuation & earnings, COAG or FTH?

Do insiders & institutionals believe in COAG or FTH?

Summary

How does Sensei Biotherapeutics compare to First Tracks Biotherapeutics?

Do analysts rate FTH or TRAX?

Which has better earnings and valuation, FTH or TRAX?

Is FTH or TRAX more profitable?

Does the media favor FTH or TRAX?

Do institutionals & insiders believe in FTH or TRAX?

Summary

How does Sensei Biotherapeutics compare to Mesoblast?

Is FTH or MESO more profitable?

Does the media favor FTH or MESO?

Do analysts rate FTH or MESO?

Which has more volatility & risk, FTH or MESO?

Which has preferable valuation and earnings, FTH or MESO?

Do insiders and institutionals hold more shares of FTH or MESO?

Summary

How does Sensei Biotherapeutics compare to Vir Biotechnology?

Which has more volatility and risk, FTH or VIR?

Do analysts prefer FTH or VIR?

Which has better valuation & earnings, FTH or VIR?

Is FTH or VIR more profitable?

Do insiders and institutionals believe in FTH or VIR?

Does the media prefer FTH or VIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools